Active Biotech (Q3 Review): Rights Issue Funds 2026-2027 - Redeye

Redeye comments on Active Biotech's third quarter report. A rights issue of SEK70m will fund the company over the next two years. The clinical studies in myelofibrosis will recommence recruitment shortly. Operating costs have decreased and are likely to remain at a lower level.

Länk till analysen i sin helhet: https://www.redeye.se/research/1137327/active-biotech-q3-review-rights-issue-funds-2026-2027?utm_source=finwire&utm_medium=RSS